Brief: Ligand Pharmaceuticals Q1 EPS USD 4.75
07/05/2024 21:00
May 07 (Reuters) - Ligand Pharmaceuticals Q1 net income continuing operations USD 86.139 million. * Q1 operating income USD 2.988 million * Q1 basic EPS USD 4.86 * Q1 pretax profit USD 113.447 million
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan